MerLion Pharmaceuticals Pte Ltd, Announces Collaboration Agreement with Sankyo Co., Ltd
MerLion Pharmaceuticals Pte Ltd (MerLion) announced a three year drug discovery and development collaboration with Sankyo Co., Ltd. (Sankyo).
Under the collaboration, Sankyo will provide selected high throughput screens and additional assays to MerLion, who will provide access to its extensive sample collection and apply its screening and experienced natural products chemistry skills to the isolation of new chemical leads. MerLion and Sankyo will work in partnership throughout the lead discovery and optimisation stages of the collaboration. Sankyo will undertake clinical development and commercialisation of the discoveries.
"This agreement with Sankyo strengthens our existing relationships with Japan and key Japanese pharmaceutical companies" said Tony Buss, PhD, CEO of MerLion. "The partnership offers both Sankyo and MerLion unique opportunities to discover novel medicines from our diverse natural products chemistry and across a wide range of therapeutic areas."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.